Abstract
Chimeric antigen receptor (CAR) T cells have radically improved the treatment of B cell-derived malignancies by targeting CD19. The success has not yet expanded to treat acute myeloid leukemia (AML). We developed a Sequentially Tumor-selected Antibody and antigen Retrieval (STAR) system to rapidly isolate multiple nanobodies (Nbs) that both preferentially bind AML cells and empower CAR T cells with anti-AML efficacy. The STAR-isolated Nb157 specifically bound CD13, which is highly expressed in AML cells, and CD13 CAR T cells potently eliminated AML in vitro and in vivo. CAR T cells bi-specific for CD13 and TIM3, which is upregulated in AML leukemia stem cells, eradicated patient-derived AML, with much reduced toxicity to human bone marrow stem cells and peripheral myeloid cells in mouse models, highlighting a promising approach for developing effective AML CAR T therapy. Copyright © 2020 American Society of Hematology.